Profile Response Detail

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile	Indication/Tumor Type	Response Type	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
KIT exon11	melanoma	predicted - sensitive	Imatinib	Phase II	Actionable	In a Phase II trial, Gleevec (imatinib) treatment resulted in a 6-month progression-free survival (PFS) rate of 36.6%, a median PFS of 3.5 months, a median overall survival (OS) of 14.0 mo, a 1-year OS rate of 51.0%, partial responses (PR) in 23.3% (10/43) and stable disease in 30.2% of metastatic melanoma patients harboring KIT mutations, 9 of the 10 responders harbored KIT exon 11/ 13 mutations (PMID: 21690468; NCT00881049).	21690468
KIT exon11	melanoma	predicted - sensitive	Imatinib	Case Reports/Case Series	Actionable	In a clinical case study, Gleevec (imatinib) treatment resulted in a partial response in a patient with metastastic anal melanoma harboring a 21 base-pair duplication in KIT exon 11, and reduced pulmonary metastasis by 60% (PMID: 20372153).	20372153
KIT exon11	melanoma	predicted - sensitive	Imatinib	Phase II	Actionable	In a Phase II trial, Gleevec (imatinib) treatment resulted in a best overall response rate of 53.8% (7/13, all partial responses), a disease control rate of 76.9% (10/13), a median time-to-progression of 3.9 months, and a median overall survival of 12.9 months in patients with mucosal, acral, or chronically sun-damaged skin melanoma harboring KIT activating mutations in exons 11 (n=9), 13 (n=3), and 17 (n=1) (PMID: 23775962; NCT00424515).	23775962

PubMed Id	Reference Title	Details
(23775962)	Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.	Full reference...
(20372153)	Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.	Full reference...
(21690468)	Phase II, open-label, single-arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplification.	Full reference...